EN DE
Watch PeptiDream Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PeptiDream Inc (PPTDF) fair value: what the stock is really worth

As of Oct 20, 2026: fair value (intrinsic value) of PeptiDream Inc stock $5.34, price $6.80, that is 21.5% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Japan

PI PeptiDream Inc logo Thin data Nov 10, 2026

PeptiDream Inc

PPTDF · US
Expensive, weak quality

Our calculation puts a fair price 21% below what the stock costs today.

Low debt
Quality 40/100
Mixed vs. peers (5/10)
Fair value $5.34 · Overvalued
Weak Growth (revenue 3y −11.6 %/yr in USD)
Loss-making · -18.9% net margin (TTM)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch PeptiDream Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$60.33 $5.88 Fair Value $5.34 Mar 2016 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $5.88 – $60.33 · fair‑value band $4.01 – $6.68 · the $6.80 price screens above the $5.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow PeptiDream in your weekly email

Every Wednesday you see whether PeptiDream is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.

Show moreShow less

The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns.

It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage.

The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage.

In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage.

Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.

Stock analysis

PeptiDream Inc (PPTDF) currently trades at $6.80, while our estimate is $5.34, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.01 (bear) to $6.68 (bull), the price of $6.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

PeptiDream Inc reported revenue of ¥18.5B in FY2025 versus ¥9.4B in FY2021, a compound +18.6%/yr. Reported net income was −¥3.8B in FY2025.

Key figures

Market cap $874M Small · P/S ratio 0.05 · EPS (TTM) $−0.1800 · Net margin −20.2% · Return on equity −7.1% · Return on assets (EBIT) 11.3% (5-year average) · Operating margin −31.3% · Revenue (TTM) ¥19.2B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −21%, PPTDF screens richer than that median.

Fair Value

Bear $4.01 Fair Value $5.34 Bull $6.68
Price $6.80 · Downside -21.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 48
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 30
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 86
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−60.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Start year 2020 (pandemic). Over 10 years: +15.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
59.9% (2020) → −26.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PPTDF screens overvalued: fair value 21% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare PeptiDream Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −21.5% · Above median
Profitability
Return on assets −4.9% · Above median
Net margin (12 months) −18.9% · Below median
Operating margin (12 months) −31.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 3.5% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.69× · Pricier than median
P/S (12 months) 7.23× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 0
FUTURE (revenue growth)18 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs PPTDF
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs PPTDF
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs PPTDF
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs PPTDF
argenx SE ARGX $971.55 $908.40 −7% vs PPTDF
CSL Limited CSL A$201.68 A$181.40 −10% vs PPTDF
Moderna, Inc MRNA $250.83 $158.70 −37% vs PPTDF
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs PPTDF
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs PPTDF
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs PPTDF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PeptiDream Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PeptiDream Inc Fair Value". https://www.fairvalue-calculator.com/stock/PPTDF

Frequently asked questions

Is PeptiDream Inc (PPTDF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $5.34 versus the last price from Oct 20, 2026 of $6.80, about 21% lower (overvalued).
What is the fair value of PPTDF?
Our estimate for PeptiDream Inc is $5.34 (as of Nov 10, 2026), built from audited fundamentals. Last price (from Oct 20, 2026): $6.80.
What is the quality score of PPTDF?
PeptiDream Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PeptiDream Inc (PPTDF)?
Our calculated price target is the estimate of $5.34 (as of Nov 10, 2026). Cautious scenario $4.01, optimistic scenario $6.68. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the PeptiDream Inc stock forecast for 2026?
Our estimate puts fair value at $5.34, about 21% lower versus the last price from Oct 20, 2026 of $6.80 (overvalued). Cautious scenario $4.01, optimistic scenario $6.68. The calculation is refreshed regularly with new filings.
What is the revenue of PeptiDream Inc (PPTDF)?
PeptiDream Inc reported trailing-twelve-month revenue of about ¥19.2B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of PeptiDream Inc (PPTDF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PeptiDream Inc it is $5.34 per share (as of Nov 10, 2026), against a price of $6.80.
Is PeptiDream Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PPTDF trades above its calculated fair value: price $6.80, fair value $5.34, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PPTDF?
No. The price is what the market pays today ($6.80); the fair value is what the company's own numbers justify ($5.34). For PeptiDream Inc the two are $1.46 per share apart. That gap is exactly why we show both numbers side by side.
How much is PeptiDream Inc worth?
The market values PeptiDream Inc at about $874M (market capitalisation, as of Nov 10, 2026). Per share that is $6.80; our models calculate a fair value of $5.34 per share.
What do the bullish and bearish scenarios say about PPTDF?
Our models span a range for PeptiDream Inc: cautious scenario $4.01, base $5.34, optimistic $6.68 per share (as of Nov 10, 2026, price $6.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PeptiDream Inc (PPTDF)?
Balance-sheet figures for PeptiDream Inc (as of Nov 10, 2026): return on equity −7.1%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is PPTDF from its 52-week high?
PeptiDream Inc trades at $6.80, about 47% below its 52-week high of $12.80 and 16% above the low of $5.88 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $5.34 is for.
Which stocks are comparable to PeptiDream Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PeptiDream Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $6.80, calculated fair value $5.34 (−21%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. PeptiDream Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PeptiDream Inc (PPTDF)?
The latest price we hold is from Oct 20, 2026 and stands at $6.80. Our estimate is $5.34, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PeptiDream Inc right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of PeptiDream Inc (PPTDF) come from?
Earnings per share at PeptiDream Inc grew +28.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +32.3 %, EBIT margin −3.6 %, tax rate +2.2 %, residual (interest, one-offs) −1.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of PeptiDream Inc

How large is the market capitalisation of PeptiDream Inc (PPTDF)?
The market capitalisation of PeptiDream Inc is $874M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PeptiDream Inc (PPTDF)?
The price-to-sales ratio of PeptiDream Inc is 0.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PeptiDream Inc (PPTDF)?
Earnings per share at PeptiDream Inc are $−0.1800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PeptiDream Inc (PPTDF)?
The net margin of PeptiDream Inc is −20.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PeptiDream Inc (PPTDF)?
The return on equity (ROE) of PeptiDream Inc is −7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PeptiDream Inc (PPTDF)?
On an EBIT basis the return on assets of PeptiDream Inc is 11.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PeptiDream Inc (PPTDF)?
The operating margin of PeptiDream Inc is −31.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PeptiDream Inc (PPTDF)?
Revenue at PeptiDream Inc is growing +3.5% versus a year earlier (3y avg −11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PeptiDream Inc (PPTDF)?
Earnings per share at PeptiDream Inc are growing +352% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does PeptiDream Inc (PPTDF) generate?
The free cash flow of PeptiDream Inc is −¥14.9B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does PeptiDream Inc (PPTDF) hold?
PeptiDream Inc holds more cash than debt, ¥11.7B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch PeptiDream Inc in the live analysis

One click puts PeptiDream Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.